{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:16:43Z","timestamp":1778102203893,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"crossref","award":["COMMONWEALTH APPROACH TO MARKET (ATM) REFERENCE NO. F21\/113"],"award-info":[{"award-number":["COMMONWEALTH APPROACH TO MARKET (ATM) REFERENCE NO. F21\/113"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012737","name":"Department of Health and Human Services, State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cancer is associated with excess morbidity and mortality from coronavirus disease 2019 (COVID-19) following infection by the novel pandemic coronavirus SARS-CoV-2. Vaccinations against SARS-CoV-2 have been rapidly developed and proved highly effective in reducing the incidence of severe COVID-19 in clinical trials of healthy populations. However, patients with cancer were excluded from pivotal clinical trials. Early data suggest that vaccine response is less robust in patients with immunosuppressive conditions or treatments, while toxicity and acceptability of COVID-19 vaccines in the cancer population is unknown. Unanswered questions remain about the impact of various cancer characteristics (such as treatment modality and degree of immunosuppression) on serological response to and safety of COVID-19 vaccinations. Furthermore, as the virus and disease manifestations evolve, ongoing data is required to address the impact of new variants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>SerOzNET is a prospective observational study of adults and children with cancer undergoing routine SARS-CoV-2 vaccination in Australia. Peripheral blood will be collected and processed at five timepoints (one pre-vaccination and four post-vaccination) for analysis of serologic responses to vaccine and exploration of T-cell immune correlates. Cohorts include: solid organ cancer (SOC) or haematological malignancy (HM) patients currently receiving (1) chemotherapy, (2) immune checkpoint inhibitors (3) hormonal or targeted therapy; (4) patients who completed chemotherapy within 6\u201312\u00a0months of vaccination; (5) HM patients with conditions associated with hypogammaglobulinaemia or immunocompromise; (6) SOC or HM patients with allergy to PEG or polysorbate 80. Data from healthy controls already enrolled on several parallel studies with comparable time points will be used for comparison. For children, patients with current or prior cancer who have not received recent systemic therapy will act as controls. Standardised scales for quality-of-life assessment, patient-reported toxicity and vaccine hesitancy will be obtained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The SerOzNET study was commenced in June 2021 to prospectively study immune correlates of vaccination in specific cancer cohorts. The high proportion of the Australian population na\u00efve to COVID-19 infection and vaccination at study commencement has allowed a unique window of opportunity to study vaccine-related immunity. Quality of life and patient-reported adverse events have not yet been reported in detail post-vaccination for cancer patients.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>This trial is registered on the Australia New Zealand Clinical Trials Registry (ANZCTR) ACTRN12621001004853. Submitted for registration 25 June 2021. Registered 30 July 2021 (Retrospectively registered).<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=382281&amp;isReview=true\">https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=382281&amp;isReview=true<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-021-07019-1","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T10:02:27Z","timestamp":1642672947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"actrn12621001004853","registry":"10.18810\/anzctr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-8485","authenticated-orcid":false,"given":"Amy","family":"Body","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Ahern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxi","family":"Lal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Downie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Turville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Mee Ling","family":"Munier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Raina","family":"MacIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"7019_CR1","unstructured":"Johns Hopkins Coronavirus Resource Center. https:\/\/coronavirus.jhu.edu\/. Accessed 12 July 2021."},{"key":"7019_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/GO.20.00639","volume":"7","author":"R Riera","year":"2021","unstructured":"Riera R, Bagattini \u00c2M, Pacheco RL, Pachito DV, Roitberg F, Ilbawi A. Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review. JCO Glob Oncol. 2021;7:311\u201323.","journal-title":"JCO Glob Oncol"},{"key":"7019_CR3","unstructured":"Australian Institute of Health and Welfare, cancer screening and COVID-19 in Australia, how has COVID-19 affected Australia\u2019s cancer screening programs?\u2014Australian Institute of Health and Welfare. https:\/\/www.aihw.gov.au\/reports\/cancer-screening\/cancer-screening-and-covid-19-in-australia\/contents\/how-has-covid-19-affected-australias-cancer-screening-programs. Accessed 5 Oct 2021."},{"key":"7019_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5694\/mja2.50968","volume":"214","author":"L te Marvelde","year":"2021","unstructured":"te Marvelde L, Wolfe R, McArthur G, Blake LA, Evans SM. Decline in cancer pathology notifications during the 2020 COVID-19-related restrictions in Victoria. Med J Aust. 2021;214:281\u20133.","journal-title":"Med J Aust"},{"key":"7019_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/CCI.20.00068","volume":"4","author":"JW London","year":"2020","unstructured":"London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 pandemic on cancer-related patient encounters. JCO Clin Cancer Inform. 2020;4:657\u201365.","journal-title":"JCO Clin Cancer Inform"},{"issue":"8","key":"7019_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(20)30388-0","volume":"21","author":"C Maringe","year":"2020","unstructured":"Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023\u201334.","journal-title":"Lancet Oncol"},{"issue":"6","key":"7019_CR7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","volume":"10","author":"M Dai","year":"2020","unstructured":"Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783\u201391.","journal-title":"Cancer Discov"},{"issue":"2","key":"7019_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","volume":"7","author":"Q Wang","year":"2021","unstructured":"Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021;7(2):220\u20137.","journal-title":"JAMA Oncol"},{"issue":"23","key":"7019_CR9","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1002\/cam4.3423","volume":"9","author":"A Ramaswamy","year":"2020","unstructured":"Ramaswamy A, Nayak L, Moulik NR, Sengar M, Chinnaswamy G, Jobanputra K, et al. COVID-19 in cancer patients on active systemic therapy\u2014outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Med. 2020;9(23):8747\u201353. https:\/\/doi.org\/10.1002\/cam4.3423.","journal-title":"Cancer Med"},{"issue":"30","key":"7019_CR10","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.20.01307","volume":"38","author":"J Jee","year":"2020","unstructured":"Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2020;38(30):3538\u201346.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7019_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00277-020-04328-4","volume":"100","author":"MM R\u00fcthrich","year":"2020","unstructured":"R\u00fcthrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolff S, Gr\u00fcner B, et al. COVID-19 in cancer patients: clinical characteristics and outcome\u2014an analysis of the LEOSS registry. Ann Hematol. 2020;100(2):383\u201393. https:\/\/doi.org\/10.1007\/s00277-020-04328-4.","journal-title":"Ann Hematol"},{"issue":"9","key":"7019_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/cncr.33386","volume":"127","author":"A Desai","year":"2021","unstructured":"Desai A, Gupta R, Advani S, Ouellette L, Kuderer NM, Lyman GH, et al. Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies. Cancer. 2021;127(9):1459\u201368.","journal-title":"Cancer"},{"issue":"10","key":"7019_CR13","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/S1470-2045(21)00454-X","volume":"22","author":"S Mukkada","year":"2021","unstructured":"Mukkada S, Bhakta N, Chantada GL, Chen Y, Vedaraju Y, Faughnan L, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021;22(10):1416\u201326.","journal-title":"Lancet Oncol"},{"key":"7019_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.07.21259779v1","author":"C Smith","year":"2021","unstructured":"Smith C, Odd D, Harwood R, Ward J, Linney M, Clark M, et al. Deaths in children and young people in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.07.07.21259779v1.","journal-title":"medRxiv"},{"issue":"5","key":"7019_CR15","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-4642(21)00066-3","volume":"5","author":"SS Bhopal","year":"2021","unstructured":"Bhopal SS, Bagaria J, Olabi B, Bhopal R. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Health. 2021;5(5):e12\u20133.","journal-title":"Lancet Child Adolesc Health"},{"issue":"23","key":"7019_CR16","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291\u20133. https:\/\/doi.org\/10.1056\/NEJMc2031364.","journal-title":"N Engl J Med"},{"issue":"2","key":"7019_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.kint.2021.05.011","volume":"100","author":"S Caillard","year":"2021","unstructured":"Caillard S, Chavarot N, Bertrand D, Kamar N, Thaunat O, Moal V, et al. Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int. 2021;100(2):477\u20139.","journal-title":"Kidney Int"},{"key":"7019_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2108861","author":"N Kamar","year":"2021","unstructured":"Kamar N, Abravanel F, Marion O, Couat C, Izopet J, del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMc2108861.","journal-title":"N Engl J Med"},{"key":"7019_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2244","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n2244.","journal-title":"BMJ"},{"key":"7019_CR20","doi-asserted-by":"publisher","first-page":"S1337","DOI":"10.1016\/j.annonc.2021.08.2140","volume":"32","author":"S Oosting","year":"2021","unstructured":"Oosting S, Van der Veldt AA, GeurtsvanKessel CH, Fehrmann RS, Van Binnendijk RS, Dingemans AC, et al. LBA8 vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors. Ann Oncol. 2021;32:S1337.","journal-title":"Ann Oncol"},{"key":"7019_CR21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s43018-021-00274-w","volume":"2","author":"A Fendler","year":"2021","unstructured":"Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Byrne F, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2:1305\u201320.","journal-title":"Nat Cancer"},{"issue":"8","key":"7019_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.annonc.2021.04.020","volume":"32","author":"R Palich","year":"2021","unstructured":"Palich R, Veyri M, Marot S, Vozy A, Gligorov J, Maingon P, et al. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Ann Oncol. 2021;32(8):1051\u20133.","journal-title":"Ann Oncol"},{"issue":"8","key":"7019_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","volume":"7","author":"A Massarweh","year":"2021","unstructured":"Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133\u201340.","journal-title":"JAMA Oncol"},{"issue":"6","key":"7019_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin L, Laing AG, Mu\u00f1oz-Ruiz M, McKenzie DR, del Barrio IDM, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765\u201378.","journal-title":"Lancet Oncol"},{"issue":"8","key":"7019_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","volume":"39","author":"A Thakkar","year":"2021","unstructured":"Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081-1090.e2.","journal-title":"Cancer Cell"},{"issue":"8","key":"7019_CR26","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis K, \u0160ablauskas K, Ringelevi\u010di\u016bt\u0117 U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583\u201392.","journal-title":"Lancet Haematol"},{"issue":"8","key":"7019_CR27","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","volume":"39","author":"O van Oekelen","year":"2021","unstructured":"van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39(8):1028\u201330.","journal-title":"Cancer Cell"},{"issue":"7868","key":"7019_CR28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572\u20137.","journal-title":"Nature"},{"key":"7019_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.17.21259027v2","author":"PA Swanson","year":"2021","unstructured":"Swanson PA, Padilla M, Hoyland W, McGlinchey K, Fields PA, Bibi S, et al. T-cell mediated immunity after AZD1222 vaccination: a polyfunctional spike-specific Th1 response with a diverse TCR repertoire. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.06.17.21259027v2.","journal-title":"medRxiv"},{"issue":"1","key":"7019_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.intimp.2013.11.009","volume":"18","author":"A Noguchi","year":"2014","unstructured":"Noguchi A, Kaneko T, Naitoh K, Saito M, Iwai K, Maekawa R, et al. Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. Int Immunopharmacol. 2014;18(1):90\u20137.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"7019_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","volume":"385","author":"RW Frenck Jr","year":"2021","unstructured":"Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239\u201350.","journal-title":"N Engl J Med"},{"key":"7019_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","volume":"22","author":"B Waissengrin","year":"2021","unstructured":"Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22:581\u20133.","journal-title":"Lancet Oncol"},{"issue":"22","key":"7019_CR33","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa2104840.","journal-title":"N Engl J Med"},{"key":"7019_CR34","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","volume":"9","author":"A Banerji","year":"2021","unstructured":"Banerji A, Wickner PG, Saff R, Stone CA, Robinson LB, Long AA, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9:1423\u201337.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"7019_CR35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/imj.15339","volume":"51","author":"Y Kanjanapan","year":"2021","unstructured":"Kanjanapan Y, Blinman P, Underhill C, Karikios D, Segelov E, Yip D. Medical Oncology Group of Australia position statement: COVID -19 vaccination in patients with solid tumours. Intern Med J. 2021;51(6):955\u20139.","journal-title":"Intern Med J"},{"issue":"6","key":"7019_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252400","volume":"16","author":"T Kompas","year":"2021","unstructured":"Kompas T, Grafton RQ, Che TN, Chu L, Camac J. Health and economic costs of early and delayed suppression and the unmitigated spread of COVID-19: the case of Australia. PLoS ONE. 2021;16(6): e0252400. https:\/\/doi.org\/10.1371\/journal.pone.0252400.","journal-title":"PLoS ONE"},{"issue":"8","key":"7019_CR37","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1016\/S2468-2667(21)00133-X","volume":"6","author":"CR Lane","year":"2021","unstructured":"Lane CR, Sherry NL, Porter AF, Duchene S, Horan K, Andersson P, et al. Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study. Lancet Public Health. 2021;6(8):e547\u201356.","journal-title":"Lancet Public Health"},{"key":"7019_CR38","unstructured":"Australia: the latest coronavirus counts, charts and maps. https:\/\/graphics.reuters.com\/world-coronavirus-tracker-and-maps\/countries-and-territories\/australia\/. Accessed 27 July 2021."},{"key":"7019_CR39","unstructured":"COVID-19 data explorer\u2014our world in data. https:\/\/ourworldindata.org\/explorers\/coronavirus-data-explorer?zoomToSelection=true&time=2021-07-17&pickerSort=desc&pickerMetric=total_vaccinations_per_hundred&Metric=People+fully+vaccinated&Interval=Cumulative&Relative+to+Population=true&Align+outbreaks=false&country=AUS~AUT~BEL~CAN~CHE~CHL~COL~CZE~DEU~DNK~ESP~EST~FIN~FRA~GBR~GRC~HUN~IRL~ISL~ISR~ITA~JPN~KOR~LTU~LUX~LVA~MEX~NLD~NOR~NZL~POL~PRT~SVK~SVN~SWE~TUR~USA~CRI. Accessed 28 July 2021."},{"key":"7019_CR40","unstructured":"SeroNet resources for researchers and clinicians | Center for Strategic Scientific Initiatives (CSSI). https:\/\/cssi.cancer.gov\/seronet. Accessed 6 July 2021."},{"key":"7019_CR41","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291720005188","author":"D Freeman","year":"2021","unstructured":"Freeman D, Loe BS, Chadwick A, Vaccari C, Waite F, Rosebrock L, et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol Med. 2021. https:\/\/doi.org\/10.1017\/S0033291720005188.","journal-title":"Psychol Med"},{"key":"7019_CR42","unstructured":"EORTC QLQ-C30 (version 3). 1995. https:\/\/qol.eortc.org\/questionnaires\/."},{"key":"7019_CR43","unstructured":"Varni JW. PedsQL TM (Pediatric Quality of Life Inventory TM). https:\/\/www.pedsql.org\/index.html. Accessed 27 Sept 2021."},{"key":"7019_CR44","unstructured":"Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/. Accessed 5 July 2021."},{"issue":"7","key":"7019_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003656","volume":"18","author":"F Tea","year":"2021","unstructured":"Tea F, Stella AO, Aggarwal A, Darley DR, Pilli D, Vitale D, et al. SARS-CoV-2 neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants. PLoS Med. 2021;18(7): e1003656. https:\/\/doi.org\/10.1371\/journal.pmed.1003656.","journal-title":"PLoS Med"},{"key":"7019_CR46","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.21.21258528","author":"S Feng","year":"2021","unstructured":"Feng S, Phillips Mmath DJ, White Phd T, Sayal Phd H, Aley PK, Phd SB, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.06.21.21258528.","journal-title":"medRxiv"},{"issue":"5","key":"7019_CR47","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.immuni.2021.04.006","volume":"54","author":"KE Lineburg","year":"2021","unstructured":"Lineburg KE, Grant EJ, Swaminathan S, Chatzileontiadou DSM, Szeto C, Sloane H, et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity. 2021;54(5):1055-1065.e5.","journal-title":"Immunity"},{"issue":"9","key":"7019_CR48","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","volume":"3","author":"SK Mahil","year":"2021","unstructured":"Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021;3(9):e627\u201337.","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"7019_CR49","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","volume":"39","author":"A Addeo","year":"2021","unstructured":"Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, di Marco M, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091\u20138.","journal-title":"Cancer Cell"},{"issue":"8","key":"7019_CR50","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","volume":"32","author":"J Barri\u00e8re","year":"2021","unstructured":"Barri\u00e8re J, Chamorey E, Adjtoutah Z, Castelnau O, Mahamat A, Marco S, et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol. 2021;32(8):1053.","journal-title":"Ann Oncol"},{"issue":"6","key":"7019_CR51","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","volume":"8","author":"S Bird","year":"2021","unstructured":"Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8(6):e389.","journal-title":"Lancet Haematol"},{"issue":"10249","key":"7019_CR52","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467.","journal-title":"Lancet"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-07019-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-07019-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-07019-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T21:33:23Z","timestamp":1674509603000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-07019-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7019"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-07019-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SerOzNET study is performed according to the Declaration of Helsinki and the National Health and Medical Research Council (Australia) Statement on Ethical Conduct in Human Research (2018). Multisite ethics approval was granted by the lead site Human Research Ethics Committee, Monash Health (HREC\/76506\/MonH-2021-268415) prior to study commencement. Written informed consent according to Good Clinical Practice principles is given by each participant prior to the commencement of any study activities, or in the case of children, by their legal guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RM has consulted for or been on advisory boards for Seqirus, AstraZeneca and Janssen on COVID-19 vaccines. She has been a panellist on a WHO research and development consultation on COVID-19 vaccines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}